STRATEGIC NEWS WATCH — August 24, 2026
|
Roche’s Genentech committed $190 million upfront and up to $2.3 billion to license Hanmi’s HM17321, a Phase 1 non-incretin obesity drug engineered to preserve muscle while stripping fat — an outlay normally reserved for far-later-stage assets, placed on a mechanism that has no human efficacy data behind it yet. Today’s top developments:
|
What to Watch
- Capricor’s November 22 decision — The extended PDUFA date is now the binary event for deramiocel. The open question is whether the FDA clears a narrowed upper-limb-function indication over the 9–3 negative July adcomm; approval on a refined label after a rejection vote would set a rare precedent for the Duchenne field.
- AAV long-term safety surveillance — Regenxbio’s spinal masses surfaced only because participants were imaged three to six years post-dose. The field’s next test is whether the FDA extends structured long-term imaging requirements across AAV gene-therapy programs, and whether Regenxbio can establish a background prevalence in Hunter syndrome, where spine MRIs are not routine.
- Elecsys pTau217 pathway and reimbursement — The clearance route and performance characteristics were not disclosed in launch coverage. Attention now turns to the CPT coding and payer coverage decisions that determine whether a primary-care amyloid triage test actually gets ordered outside the specialist setting anti-amyloid therapies depend on.
- First-line TNBC consolidating around ADCs — Trodelvy’s EU nod adds a second ADC-anchored option to first-line PD-L1-positive triple-negative breast cancer alongside AstraZeneca and Daiichi Sankyo’s Datroway. The competitive question is shifting from whether to use an ADC up front to which one, and on what biomarker.
- HM17321’s Phase 1 readout — Hanmi completes the first-in-human study before Genentech assumes development from Phase 2. The data point that matters is the first human body-composition readout on a UCN2 analog — the moment the muscle-preservation thesis behind a $2.3 billion biodollar deal either survives or does not.
This brief highlights the edition’s top stories. Read the full August 24, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.